A Phase 2 interventional study of LNP023 and Rituximab in Idiopathic Membranous Nephropathy, sponsored by Novartis Pharmaceuticals. Terminated at 18 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a randomized, open-label, two arm, parallel group, proof-of-concept, nonconfirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with Idiopathic (primary) membranous nephropathy (iMN) who are at high risk of disease progression defined on the basis of anti- Phospholipase A2 Receptor (PLA2R) antibody titer ≥ 60 RU/mL and proteinuria with urine protein (UP) ≥ 3.5 g/24h.
The overall study was planned for a total of 65 weeks and included:
As per protocol amendment V01, subjects were randomized 1:1 to LNP023 (investigational drug) or Rituximab (comparator) and followed the below dosing schedule:
Initially, per protocol V00, subjects were planned to be randomized in a 1:1:1 ratio to 3 treatment arms:
Following protocol amendment 1 implementation, ongoing subjects were switched to 200mg b.i.d. dose after their initial 4 weeks of treatment.
3 subjects completed treatment under protocol V00. PK/PD data from the 3 completing subjects under protocol V00 are not included in the study results.
The main reason for protocol amendment V01 was to align with the clinical study results obtained from the interim analysis of ongoing phase 2 trials with LNP023 which had shown a dose dependent inhibition of the complement alternative pathway and support best efficacy results with LNP023 at a dose level of 200mg.
The study was early terminated as LNP023 after interim analysis of 12 LNP023 and 14 rituximab subjects because it could already be predicted at that point that the primary goal of superiority of LNP023 vs rituximab in the reduction of UPCR at 24 weeks was not possible to achieve if the study continued to completion.
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
This study's enrollment of 37 is below the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Browse Glomerulonephritis, Membranous studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
As per protocol V00, participants took LNP023 10 mg orally b.i.d. for 4 weeks followed by LNP023 50 mg orally b.i.d. for 20 weeks. As per protocol amendment V01, participants took LNP023 50mg orally b.i.d. for 4 weeks followed by LNP023 200mg for 20 weeks.
Drug: LNP023
Rituximab 1 g i.v. at Day 1 and Day 15
Drug: Rituximab
Ratio Between Baseline Urine Protein Creatinine Ratio (UPCR) and Urine Protein Creatinine Ratio at 24 Weeks of Treatment (From 24h Urine Collection)
The primary endpoint of this study is the ratio between UPCR at 24 weeks of treatment measured in 24h urine and baseline UPCR . To assess the primary objective, the log-transformed ratio to baseline in UPCR was analyzed using a mixed model for repeated measures (MMRM). The results were back transformed and presented on the original scale.
Time frame: Baseline, Day 113, Day 169
Change From Baseline in Plasma Levels of Circulating Fragment of Factor B (Bb)
The drug (LNP023) is expected to block the complement alternative pathway dysregulation and thereby should normalize complement biomarker levels in serum. Bb is a biomarker that accurately reflects the level of complement Alternative Pathway activation. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.
Time frame: Baseline, Day 15, Day 29, Day 57, Day 113 and Day 169
Change From Baseline in Plasma Levels of sC5b-9
Soluble C5b-9 (sC5b-9) is a biomarker of the complement pathway activity that correlate with disease progression. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.
Time frame: Baseline, Day 15, Day 29, Day 57, Day 113, Day 169
Ratio to Baseline of Urine Protein Creatinine Ratio (UPCR) Measured in First Morning Void
Adjusted geometric mean ratio to baseline of Urine Protein Creatinine Ratio (UPCR) measured in first morning void. First morning void urine sample was collected in the morning of the day before the visit and kept in the fridge.
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 266 and Day 378
Number of Participants by Treatment Response at 24 Weeks of Treatment
Participants were considered complete responders if at 24 weeks of treatment, they showed complete remission of proteinuria (i.e., Urine Protein (UP) ≤ 0.3 g/24h), partial responders if they showed partial remission (i.e., UP \> 0.3g/24h and ≤ 3.5 g/24h and a reduction of UP by \>50% from baseline), and non-responders if UP \>3.5g/24h and/or reduction of UP from baseline \<50%.
Time frame: Baseline, Day 169
Change From Baseline in (eGFR) Estimated Glomerular Filtration Rate Over Time
Changes in renal function were assessed via estimated glomerular filtration rate (eGFR). Change in eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Time frame: Baseline, Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Pharmacokinetic Parameter Tmax in Plasma
Pharmacokinetics of LNP023 : Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time). Actual sampling time points were considered for the calculation of PK parameters.
Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Pharmacokinetic Parameter Cmax in Plasma
Pharmacokinetics of LNP023: Cmax is the maximum (peak) observed plasma drug concentration after dose administration (mass x volume-1)
Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Pharmacokinetic Parameter AUClast in Plasma
Pharmacokinetics of LNP023: AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)
Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Pharmacokinetic Parameter AUCtau in Plasma
Pharmacokinetics of LNP023 : AUCtau is the AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)
Time frame: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Pharmacokinetics in Urine: Renal Plasma Clearance Derived From 24 Hour Urine Sample
Pharmacokinetics of LNP023 in urine: Renal plasma clearance derived from 24 hour urine sample
Time frame: Day 113
Participants took part in 18 investigative sites in 9 countries/regions: Argentina (3), Czech Republic (1), Germany (4), India (2), Netherlands (1), Spain (2), United Kingdom (3), China (1) and Taiwan (1)
| Milestone | LNP023 10/50 mg b.i.d. | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|---|
| Started | 3 | 19 | 15 |
| Completed | 3 | 9 | 14 |
| Not completed | 0 | 10 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Patient requires other treatment | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 6 | 1 |
| Withdrew: Subject decision | 0 | 1 | 0 |
| Withdrew: Suspected lack of efficacy | 0 | 1 | 0 |
The primary endpoint of this study is the ratio between UPCR at 24 weeks of treatment measured in 24h urine and baseline UPCR . To assess the primary objective, the log-transformed ratio to baseline in UPCR was analyzed using a mixed model for repeated measures (MMRM). The results were back transformed and presented on the original scale.
| ratio to baseline | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|
| Day 113 | 0.94 (0.74 to 1.20) | 0.89 (0.71 to 1.10) |
| Day 169 | 0.88 (0.65 to 1.19) | 0.64 (0.48 to 0.86) |
The drug (LNP023) is expected to block the complement alternative pathway dysregulation and thereby should normalize complement biomarker levels in serum. Bb is a biomarker that accurately reflects the level of complement Alternative Pathway activation. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.
| ng/mL | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|
| Day 15 | 1520.59 ± 9370.086 | -417.69 ± 701.667 |
| Day 29 | -732.00 ± 1412.633 | -318.46 ± 604.440 |
| Day 57 | -545.00 ± 1379.201 | -75.38 ± 787.545 |
| Day 113 | -877.27 ± 1562.716 | -219.17 ± 703.568 |
| Day 169 | -984.00 ± 1794.419 | -570.00 ± 611.167 |
Soluble C5b-9 (sC5b-9) is a biomarker of the complement pathway activity that correlate with disease progression. Baseline is defined as the last non-missing measurement prior to randomization. Measurements for LNP023 group were done pre-dose.
| ng/mL | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|
| Day 15 | -80.40 ± 98.229 | -38.49 ± 52.258 |
| Day 29 | -82.80 ± 118.338 | -24.51 ± 94.826 |
| Day 57 | -90.62 ± 108.483 | -14.02 ± 107.651 |
| Day 113 | -113.32 ± 108.118 | -24.95 ± 128.721 |
| Day 169 | -84.07 ± 96.045 | -21.76 ± 122.654 |
Adjusted geometric mean ratio to baseline of Urine Protein Creatinine Ratio (UPCR) measured in first morning void. First morning void urine sample was collected in the morning of the day before the visit and kept in the fridge.
| ratio to baseline | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|
| Day 15 | 0.94 (0.65 to 1.34) | 1.15 (0.75 to 1.76) |
| Day 29 | 0.98 (0.70 to 1.36) | 0.90 (0.60 to 1.35) |
| Day 57 | 1.02 (0.71 to 1.48) | 0.77 (0.51 to 1.16) |
| Day 85 | 1.03 (0.68 to 1.56) | 0.75 (0.50 to 1.13) |
| Day 113 | 1.05 (0.68 to 1.63) | 0.92 (0.60 to 1.41) |
| Day 141 | 0.75 (0.48 to 1.19) | 0.77 (0.48 to 1.23) |
| Day 169 | 0.72 (0.44 to 1.16) | 0.55 (0.34 to 0.89) |
| Day 266 | 0.57 (0.33 to 0.99) | 0.34 (0.20 to 0.57) |
| Day 378 (End Of Study) | 0.37 (0.22 to 0.63) | 0.46 (0.27 to 0.76) |
Participants were considered complete responders if at 24 weeks of treatment, they showed complete remission of proteinuria (i.e., Urine Protein (UP) ≤ 0.3 g/24h), partial responders if they showed partial remission (i.e., UP \> 0.3g/24h and ≤ 3.5 g/24h and a reduction of UP by \>50% from baseline), and non-responders if UP \>3.5g/24h and/or reduction of UP from baseline \<50%.
| Participants | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|
| Complete | 0 | 0 |
| Partial | 2 | 2 |
| No response | 7 | 7 |
Changes in renal function were assessed via estimated glomerular filtration rate (eGFR). Change in eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
| mL/min/1.73 m^2 | LNP023 200 mg b.i.d. | Rituximab |
|---|---|---|
| Day 15 | 2.3 ± 12.07 | 0.3 ± 8.33 |
| Day 29 | -0.5 ± 8.53 | 6.1 ± 10.44 |
| Day 57 | 2.0 ± 11.10 | 9.2 ± 21.05 |
| Day 85 | -1.6 ± 11.53 | 10.2 ± 16.40 |
| Day 113 | 1.2 ± 8.64 | 10.8 ± 15.41 |
| Day 141 | -1.8 ± 9.10 | 7.1 ± 9.29 |
| Day 169 | -1.3 ± 7.36 | 3.1 ± 13.21 |
Pharmacokinetics of LNP023 : Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time). Actual sampling time points were considered for the calculation of PK parameters.
| hours | LNP023 10 mg b.i.d. | LNP023 25 mg b.i.d. | LNP023 50 mg b.i.d. (4-week Administration) | LNP023 50 mg b.i.d. (20-week Administration) | LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|
| Day 29 | 2.04 (2.00 to 2.08) | 2.00 (1.00 to 4.00) | 2.03 (1.00 to 4.38) | — | — |
| Day 113 | — | — | — | 2.05 (2.00 to 2.10) | 1.00 (0.250 to 6.00) |
Pharmacokinetics of LNP023: Cmax is the maximum (peak) observed plasma drug concentration after dose administration (mass x volume-1)
| ng/mL | LNP023 10 mg b.i.d. | LNP023 25 mg b.i.d. | LNP023 50 mg b.i.d. (4-week Administration) | LNP023 50 mg b.i.d. (20-week Administration) | LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|
| Day 29 | 1200 ± 799 | 2070 ± 938 | 2140 ± 917 | — | — |
| Day 113 | — | — | — | 1220 ± 304 | 4810 ± 2850 |
Pharmacokinetics of LNP023: AUClast is the AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)
| hr*ng/mL | LNP023 10 mg b.i.d. | LNP023 25 mg b.i.d. | LNP023 50 mg b.i.d. (4-week Administration) | LNP023 50 mg b.i.d. (20-week Administration) | LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|
| Day 29 | 5970 ± 4150 | 8140 ± 3080 | 9920 ± 3960 | — | — |
| Day 113 | — | — | — | 5940 ± 989 | 22200 ± 15600 |
Pharmacokinetics of LNP023 : AUCtau is the AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)
| hr*ng/mL | LNP023 10 mg b.i.d. | LNP023 25 mg b.i.d. | LNP023 50 mg b.i.d. (4-week Administration) | LNP023 50 mg b.i.d. (20-week Administration) | LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|
| Day 29 | 9850 ± 5790 | 12800 ± 3490 | 16500 ± 5920 | — | — |
| Day 113 | — | — | — | 10700 ± 1640 | 36800 ± 26100 |
Pharmacokinetics of LNP023 in urine: Renal plasma clearance derived from 24 hour urine sample
| L/hr | LNP023 50 mg b.i.d. (20-week Administration) | LNP023 200 mg b.i.d. |
|---|---|---|
| Pharmacokinetics in Urine: Renal Plasma Clearance Derived From 24 Hour Urine Sample | 0.602 | 1.19 ± 0.668 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 29 weeks post treatment, up to maximum duration of 53 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LNP023 10/50 mg b.i.d. | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| LNP023 200 mg b.i.d. | 0/19 (0%) | 3/19 (15.8%) | 13/19 (68.4%) |
| Pooled LNP023 | 0/22 (0%) | 3/22 (13.6%) | 15/22 (68.2%) |
| Rituximab | 0/15 (0%) | 4/15 (26.7%) | 7/15 (46.7%) |
| Total | 0/37 (0%) | 7/37 (18.9%) | 22/37 (59.5%) |
| Event | LNP023 10/50 mg b.i.d. | LNP023 200 mg b.i.d. | Pooled LNP023 | Rituximab | Total |
|---|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/3 | 1/19 | 1/22 | 2/15 | 3/37 |
| Acute kidney injuryRenal and urinary disorders | 0/3 | 0/19 | 0/22 | 1/15 | 1/37 |
| ErythemaSkin and subcutaneous tissue disorders | 0/3 | 0/19 | 0/22 | 1/15 | 1/37 |
| COVID-19 pneumoniaInfections and infestations | 0/3 | 1/19 | 1/22 | 0/15 | 1/37 |
| Lower respiratory tract infectionInfections and infestations | 0/3 | 1/19 | 1/22 | 0/15 | 1/37 |
| Event | LNP023 10/50 mg b.i.d. | LNP023 200 mg b.i.d. | Pooled LNP023 | Rituximab | Total |
|---|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 1/3 | 0/19 | 1/22 | 1/15 | 2/37 |
| Head injuryInjury, poisoning and procedural complications | 1/3 | 0/19 | 1/22 | 0/15 | 1/37 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/3 | 1/19 | 2/22 | 1/15 | 3/37 |
| Epididymal cystReproductive system and breast disorders | 1/3 | 0/19 | 1/22 | 0/15 | 1/37 |
| COVID-19Infections and infestations | 0/3 | 3/19 | 3/22 | 1/15 | 4/37 |
| HeadacheNervous system disorders | 0/3 | 3/19 | 3/22 | 0/15 | 3/37 |
| NasopharyngitisInfections and infestations | 0/3 | 1/19 | 1/22 | 2/15 | 3/37 |
| GoutMetabolism and nutrition disorders | 0/3 | 0/19 | 0/22 | 2/15 | 2/37 |
| FatigueGeneral disorders | 0/3 | 2/19 | 2/22 | 0/15 | 2/37 |
| Oedema peripheralGeneral disorders | 0/3 | 2/19 | 2/22 | 0/15 | 2/37 |
| Age, Continuous(years) | LNP023 10/50 mg b.i.d. | LNP023 200 mg b.i.d. | Rituximab | Total |
|---|---|---|---|---|
| Mean | 55.0 ± 18.52 | 48.9 ± 8.84 | 46.7 ± 15.33 | 48.5 ± 12.43 |
| Sex: Female, Male(Participants) | LNP023 10/50 mg b.i.d. | LNP023 200 mg b.i.d. | Rituximab | Total |
|---|---|---|---|---|
| Female | 1 | 4 | 1 | 6 |
| Male | 2 | 15 | 14 | 31 |
| Race/Ethnicity, Customized(Participants) | LNP023 10/50 mg b.i.d. | LNP023 200 mg b.i.d. | Rituximab | Total |
|---|---|---|---|---|
| Asian | 1 | 5 | 4 | 10 |
| Black Or African American | 0 | 0 | 1 | 1 |
| Unknown | 0 | 0 | 1 | 1 |
| White | 2 | 14 | 9 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Nov 2019 to primary completion in Jan 2023, 37 months.
Results were first posted in Jul 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iptacopan
Glomerulonephritis, Membranous →